Cellectis Current ratio
What is the Current ratio of Cellectis?
The Current ratio of Cellectis is 3.17
What is the definition of Current ratio?
Current ratio is a liquidity ratio that measures whether or not a company has enough resources to meet its short-term obligations.
mrq (most recent quarter)
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio of companies in the Health Care sector on NASDAQ compared to Cellectis
What does Cellectis do?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Companies with current ratio similar to Cellectis
- Clean Fuels Corp has Current ratio of 3.17
- SPS Commerce has Current ratio of 3.17
- Installux S.A has Current ratio of 3.17
- NewRiver REIT plc has Current ratio of 3.17
- Crowd Media has Current ratio of 3.17
- Pure Cycle has Current ratio of 3.17
- Cellectis has Current ratio of 3.17
- AMMO has Current ratio of 3.17
- AMMO has Current ratio of 3.17
- Eckert & Ziegler Strahlen- und Medizintechnik AG has Current ratio of 3.17
- Cadre has Current ratio of 3.17
- Besunyen has Current ratio of 3.17
- Youth Champ has Current ratio of 3.17